In the United States, 1 in 8 women will be diagnosed with invasive breast cancer.1
As the #1 lab in breast cancer testing with over 20 years of expertise, NeoGenomics offers a comprehensive suite of tests to support the entire breast cancer care continuum. From diagnosis to therapy selection, prognosis, and clinical trial options, NeoGenomics provides the expertise and precision needed at every stage of breast cancer care.
Featured breast cancer solutions
Comprehensive testing for metastatic breast cancer patients
As the precision medicine landscape for metastatic breast cancer (mBC) patients evolves, so does the need for biomarker testing. Clinical practice guidelines now recommend biomarker testing for all metastatic breast cancer patients, regardless of subtype. The NeoGenomics breast cancer solution provides comprehensive genomic profiling to help inform treatment decisions and clinical trial availability for mBC patients.
Clinically actionable biomarkers for breast cancer2-4
MSI, microsatellite instability; TMB, tumor mutation burden.
Add-on testing for therapy selection
References
Menon G, Alkabban FM, Ferguson T. Breast cancer. StatPearls [Internet]. StatPearls Publishing. Last updated February 25, 2024. Accessed December 23, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482286/
Suehnholz SP, Nissan MH, Zhang H, et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 2024;14(1):49-65.
Chakravarty D, Gao J, Phillips S, et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011.
Al Sukhun S, Temin S, Barrios CH, et al. Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2024;10:e2300285.